Simeprevir

Contraindicated

Simeprevir Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details

Major

Simeprevir Abametapir Explained Increased exposure of CYP3A4 substrate Details Simeprevir Relugolix Orgovyx Explained Increased relugolix exposure Details Simeprevir Simvastatin Flolipid Explained Increased simvastatin exposure Details Simeprevir Aliskiren Tekturna Increased exposure of P-gp substrate Details Simeprevir Ambrisentan Letairis Increased exposure of P-gp substrate Details Simeprevir Apixaban Eliquis Explained Increased exposure of the CYP3A4 and P-gp substrate Details Simeprevir Atogepant Qulipta Increased atogepant exposure Details Simeprevir Atorvastatin Atorvaliq Increased atorvastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Simeprevir Abiraterone Abirtega Increased simeprevir exposure Details Simeprevir Cyclosporine Injection Atopica Increased exposure of cycloSPORINE Details Simeprevir Cyclosporine Ophthalmic Cequa Increased exposure of cycloSPORINE Details Simeprevir Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Simeprevir Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Simeprevir Digoxin Cardoxin® Increased digoxin exposure and an increased risk of digoxin toxicity Details Simeprevir Disopyramide Norpace Increased exposure to the antiarrhythmic agent Details Simeprevir Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Simeprevir Ezetimibe Zetia Increased exposure of OATP1B1/3 substrate Details Simeprevir Fexofenadine Allegra Increased exposure of P-gp substrate Details Simeprevir Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Simeprevir Flecainide Tambocor® Increased exposure to the antiarrhythmic agent Details Simeprevir Ketoconazole Topical Extina® Foam Increased exposure of one or both drugs Details Simeprevir Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Simeprevir Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Simeprevir Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Simeprevir Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Simeprevir Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Simeprevir Methotrexate Jylamvo Increased exposure of OATP1B1/3 substrate Details Simeprevir Methotrexate Injection Abitrexate® Increased exposure of OATP1B1/3 substrate Details Simeprevir Methylergonovine Methergine Increased methylergonovine exposure Details Simeprevir Mexiletine Mexitil® Increased exposure to the antiarrhythmic agent Details Simeprevir Miconazole Buccal Oravig Increased simeprevir exposure Details Simeprevir Miconazole Topical Aloe Vesta Antifungal Increased simeprevir exposure Details Simeprevir Miconazole Vaginal Lagicam Increased simeprevir exposure Details Simeprevir Miconazole Aloe Vesta Antifungal Increased simeprevir exposure Details Simeprevir Midazolam Nasal Spray Nayzilam Increased midazolam exposure Details Simeprevir Midazolam Injection Nayzilam Increased midazolam exposure Details Simeprevir Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Simeprevir Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Simeprevir Nafcillin Injection Unipen® Injection Decreased simeprevir exposure and loss of therapeutic effect Details